TABLE 1.
Baseline Characteristics of Study Population
| Total (n=268) |
Case Patients (n=134) |
Control Patients (n=134) |
P | |
|---|---|---|---|---|
| Mean age, y (SD) | 74 (11) | 74 (11) | 74 (11) | 0.96 |
| Sex, female, % | 55.2 | 55.2 | 55.2 | 1.00 |
| Duration of monitoring, d | 291 | 287 | 298 | 0.72 |
| NYHA class, % | ||||
| I | 0.8 | 0.8 | 0.8 | 1.00 |
| II | 0.8 | 0.8 | 0.8 | 1.00 |
| III | 97.4 | 96.3 | 98.5 | 0.45 |
| IV | 1.1 | 2.2 | 0.0 | 0.25 |
| Prescribed ACEI, % | 71.3 | 67.9 | 74.6 | 0.91 |
| Prescribed β-blocker, % | 48.9 | 55.2 | 42.5 | 0.05 |
| Hypertension, % | 52.6 | 50.0 | 55.2 | 0.83 |
| Coronary artery disease, % | 45.5 | 41.0 | 50.0 | 0.18 |
| Diabetes mellitus, % | 36.6 | 35.8 | 37.3 | 0.65 |
| Stroke/TIA, % | 9.7 | 9.0 | 10.5 | 0.74 |
| Chronic obstructive pulmonary disease, % | 10.5 | 11.9 | 9.0 | 0.28 |
ACEI indicates angiotensin-converting enzyme inhibitor; TIA, transient ischemic attack.